Cargando…
In vitro metabolic characterization of the SARS-CoV-2 papain-like protease inhibitors GRL0617 and HY-17542
The SARS-CoV-2 pandemic requires a new therapeutic target for viral infection, and papain-like protease (Plpro) has been suggested as a druggable target. This in-vitro study was conducted to examine the drug metabolism of the GRL0617 and HY-17542, Plpro inhibitors. Metabolism of these inhibitors was...
Autores principales: | Cho, Hyunki, Kim, Young Jun, Chae, Jung-Woo, Meyer, Markus R., Kim, Sang Kyum, Ryu, Chang Seon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975351/ https://www.ncbi.nlm.nih.gov/pubmed/36874001 http://dx.doi.org/10.3389/fphar.2023.1067408 |
Ejemplares similares
-
Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow
por: Parmar, Paritosh, et al.
Publicado: (2021) -
Identifying structural–functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation
por: Rao, Priyashi, et al.
Publicado: (2021) -
The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery
por: Fu, Ziyang, et al.
Publicado: (2021) -
Role of Papain-Like Cysteine Proteases in Plant Development
por: Liu, Huijuan, et al.
Publicado: (2018) -
Targeting papain-like protease for broad-spectrum coronavirus inhibition
por: Yuan, Shuofeng, et al.
Publicado: (2022)